1 results match your criteria: "Suzhou Institute for Digestive Disease and Natrition[Affiliation]"
[A study of efficiacy of infliximab treatment for Crohn's disease.].
Zhonghua Nei Ke Za Zhi
November 2009
Department of Gastroenterology, Affiliated Suzhou Hospital of Nanjing Medical University/Suzhou Municipal Hospital, Suzhou Institute for Digestive Disease and Natrition, Suzhou 215008, China. Email:
Objective: To investigated the potential and safety of the monoclonal antibody to TNFalpha infliximab (IFX) in the treatment of active Crohn's disease (CD).
Methods: Patients who were confirmed diagnosis of CD and were unresponsive to the conventional treatments, or recurred after surgeries, or discontinued treatment due to drug intolerance, were treated with IFX intravenously in a dose of 5 mg/kg at week 0, 2, 6 (IFX infusion continued at an interval of every 8 weeks if respond to initial dosing). Clinical assessments, including disease activity, blood biological markers and colonoscopic findings, were performed at baseline (week 0) and each week (4 weeks or later for colonoscopy) after IFX infusion were conducted until the week before 4(th) infusion from initiated.